

Thursday November 6th, 2008

II SESSION

MOLECULAR SUBTYPES OF BREAST CANCER AND ADJUVANT OPTIONS

- 9.00 Triple negative tumors: any regimen of choice?
Chris Poole
- 9.30 HER2+ tumors: schedule and duration of anti-HER2 treatment
Denis Slamon
- 10.00 Q&A
- 10.30 Coffee break
- 11.00 HR+ tumors: role of chemotherapy
Paolo Pronzato
- 11.30 Extended adjuvant endocrine therapy: when and how
Ian Smith
- 12.00 Optimal endocrine therapy for premenopausal patients
Francesco Boccardo
- 12.30 Q&A
- 13.00 Lunch
- 14.00 Controversies in adjuvant treatment (discussion with audience and expert panel)
Discussant: Antonio Frassoldati
Clinical Panel: Matti Aapro, Francesco Boccardo, Gabriel N. Hortobagyi, Chris Poole, Paolo Pronzato, Denis Slamon, Ian Smith

Items:

- Anthracyclines: when and how?
- Taxanes: when and how?
- Still a role for Tamoxifen?
- HER2 positive disease: can we spare adjuvant trastuzumab to some patients?

III SESSION

PRIMARY SYSTEMIC THERAPY

- 15.30 State of art of primary systemic therapy in the different molecular subtypes
Gabriel N. Hortobagyi
- 16.15 Coffee break
- 16.00 Optimal imaging for response assessment in primary systemic therapy
Annarita Pecchi, Pietro Torricelli
- 17.00 Controversies in surgical management after primary systemic therapy
Michael Untch
- Potential contraindication to breast conserving surgery
 - Role of sentinel node biopsy,
 - Is surgery necessary for patients in CR?